What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives 
MIMEDX Comments on Recent Data Brief Published by Office of Inspector General
Company applauds the Office of Inspector General’s (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly...
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product
The Company unveils brand name for its planned minoxidil hair regrowth productLOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- ViaDerma,...
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2022 Financial Results
Revenue increased 9.0% to $451.1 million, compared to Q4 2021 Gross margin increased 3.5% to $128.8 million, compared to Q4...
SPR Therapeutics’ 14-Month Data from Multicenter Low Back Pain Trial Demonstrates Significant, Durable Impacts on Pain Intensity, Disability, and Pain Interference
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving...
Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as...
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving...
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of...
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating...
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address...
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical...
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE...
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash,...
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the...
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data...
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16,...
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm...